Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Reuters

2025/09/10

Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566418726"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566418726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566418726?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 06:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566418726","market":"us","top_or_hot":-1,"title":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-10 06:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL8Mttsp:1","article_id":"2566418726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566418726","pubTimestamp":1757458787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months  revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","CTKB":"Cytek BioSciences","BK4121":"生命科学工具和服务"},"translate_title":"Cytek Biosciences Inc.发布投资者演讲，重点介绍领先的细胞分析工具和2025年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":0.9},"content_text":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    \n\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}